Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Aug 12, 2019 • 9:00 AM EDT
Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China
Jul 30, 2019 • 8:00 AM EDT
Ligand Reports Second Quarter 2019 Financial Results
Jul 23, 2019 • 4:15 PM EDT
Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company
Jul 30, 2019 • 9:00am EDT
See all events
Jun 6, 2019 • 8:30am PDT
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121
May 29, 2019